Bio-Rad Introduces Nuvia™ Q, An Ultra–High Binding Capacity Anion Exchanger for Biopharmaceutical Downstream Processing
Nuvia Q Offers High Productivity, Robustness, and Selectivity
Hercules, CA — August 29, 2011 — Bio-Rad Laboratories, Inc. announces the launch of its Nuvia™Q ultra–high capacity anion exchange medium specifically designed to meet the need for robustness, high productivity, and selectivity demanded by today’s downstream processes. The launch of Nuvia Q along with the Nuvia S cation exchanger, released in late 2010, offers process developers best-in-class ion exchangers for the capture and polish stages of biopharmaceutical purification.
"Higher titer feeds resulting from improvements in upstream bioprocessing efficiencies create a purification bottleneck, making it difficult to purify large volumes of biomolecules during downstream processing," said Randy Jacinto, senior product manager in Bio-Rad’s Process Chromatography Division. "With downstream processing representing a significant amount of all manufacturing costs, the introduction of Nuvia Q addresses the need for robust, high-capacity process chromatography media that can consistently purify large volumes of drugs used in therapeutics."
Designed to meet the demanding pressure-flow requirements of commercial scale bio-processes, Nuvia Q exhibits a dynamic binding capacity of greater than 170 mg/ml at a flow rate of 300 cm/hr, approximately tripling the binding capacity of first-generation Sepharose Fast Flow media. By maintaining high binding capacity even at fast flow rates, Nuvia Q can significantly improve productivity while reducing cycle time for downstream biotherapeutics purification. Moreover, due to the high binding capacity, less media is required for a given unit operation, thereby reducing capital costs and space requirements.
Nuvia Q targets the purification of monoclonal antibodies, recombinant proteins, and vaccines. This anion exchange media, when used for the intermediate polishing of monoclonal antibodies, demonstrates high selectivity in the clearance of common contaminants in the feed stream such as dsDNA and host cell proteins. In a workflow, Nuvia Q used after capture by Bio-Rad’s UNOsphere SUPrA™ or Nuvia S media cleared host cell protein by two orders of magnitude, while dsDNA levels were reduced to below detectable levels.
Key benefits of the Nuvia Q anion exchange media:
- High binding capacity — requires less media to bind target molecules, which reduces capital expenses, increases productivity, and minimizes buffer requirements
- Excellent flow properties — produces faster flow rates without compromising dynamic binding capacity, allowing scientists to operate at higher linear velocities
- Strong selectivity — resolves closely related proteins and separates common feed stream contaminants, which produces higher-end product quality while reducing the number of purification steps required in the downstream process
- High recovery and base stability — delivers consistent and reproducible purification performance with chemical and physical stability for a high number of cycles reducing overall costs
Nuvia Q is built on the robust, industry-proven UNOsphere™ base matrix with proprietary surface extender technology. Surface modifications of the UNOsphere epoxide provide significantly higher binding capacities while maintaining fast flow rates.
For product details or to request a free sample of Nuvia Q chromatography media and screen for your process, please visit www.bio-rad.com/ad/nuvia.
About Nuvia Media
Nuvia media are a family of best-in-class ion exchangers built with exceptionally high capacities and excellent purification capabilities, providing process developers more flexibility and higher productivity. Nuvia Q and S are ultra–high capacity, next-generation ion exchange media built on the industry proven UNOsphere base matrix technology that deliver high binding capacity over a variety of pH ranges and flow rates. The chemical stability of Nuvia allows the media to withstand repeated exposure to commonly used sanitization and cleaning-in-place protocols and maintain peak performance over an extended lifetime.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The Company employs over 6,800 people globally and had revenues exceeding $1.9 billion in 2010. For more information, visit www.bio-rad.com.
For more information contact:
Bio-Rad Laboratories, Inc.
312-997-2436 x 109